Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†

This randomized phase II study examined the use of vinflunine in combination with gemcitabine or carboplatin as first-line chemotherapy in cisplatin-ineligible patients with advanced urothelial carcinoma. Both doublets were feasible and offered a similar 77% disease control rate. Response rate (44%)...

Full description

Bibliographic Details
Main Authors:	De Santis, M., Wiechno, P. J., Bellmunt, J., Lucas, C., Su, W.-C., Albiges, L., Lin, C.-C., Senkus-Konefka, E., Flechon, A., Mourey, L., Necchi, A., Loidl, W. C., Retz, M. M., Vaissière, N., Culine, S.
Format:	Online
Language:	English
Published:	Oxford University Press 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769994/

id	pubmed-4769994
recordtype	oai_dc
spelling	pubmed-47699942016-02-29 Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)† De Santis, M. Wiechno, P. J. Bellmunt, J. Lucas, C. Su, W.-C. Albiges, L. Lin, C.-C. Senkus-Konefka, E. Flechon, A. Mourey, L. Necchi, A. Loidl, W. C. Retz, M. M. Vaissière, N. Culine, S. Original Articles This randomized phase II study examined the use of vinflunine in combination with gemcitabine or carboplatin as first-line chemotherapy in cisplatin-ineligible patients with advanced urothelial carcinoma. Both doublets were feasible and offered a similar 77% disease control rate. Response rate (44%), overall survival (14 months) and less haematological toxicity favoured vinflunine–gemcitabine. Oxford University Press 2016-03 2015-12-16 /pmc/articles/PMC4769994/ /pubmed/26673352 http://dx.doi.org/10.1093/annonc/mdv609 Text en © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	De Santis, M. Wiechno, P. J. Bellmunt, J. Lucas, C. Su, W.-C. Albiges, L. Lin, C.-C. Senkus-Konefka, E. Flechon, A. Mourey, L. Necchi, A. Loidl, W. C. Retz, M. M. Vaissière, N. Culine, S.
spellingShingle	De Santis, M. Wiechno, P. J. Bellmunt, J. Lucas, C. Su, W.-C. Albiges, L. Lin, C.-C. Senkus-Konefka, E. Flechon, A. Mourey, L. Necchi, A. Loidl, W. C. Retz, M. M. Vaissière, N. Culine, S. Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†
author_facet	De Santis, M. Wiechno, P. J. Bellmunt, J. Lucas, C. Su, W.-C. Albiges, L. Lin, C.-C. Senkus-Konefka, E. Flechon, A. Mourey, L. Necchi, A. Loidl, W. C. Retz, M. M. Vaissière, N. Culine, S.
author_sort	De Santis, M.
title	Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†
title_short	Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†
title_full	Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†
title_fullStr	Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†
title_full_unstemmed	Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†
title_sort	vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase ii trial (jasint1)†
description	This randomized phase II study examined the use of vinflunine in combination with gemcitabine or carboplatin as first-line chemotherapy in cisplatin-ineligible patients with advanced urothelial carcinoma. Both doublets were feasible and offered a similar 77% disease control rate. Response rate (44%), overall survival (14 months) and less haematological toxicity favoured vinflunine–gemcitabine.
publisher	Oxford University Press
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769994/
_version_	1613544283621556224

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†

Similar Items